Skip to Content

Join the 'Vaccination' group to help and get support from people like you.

Vaccination News

Seqirus Receives FDA Approval for Afluria Quadrivalent (Influenza Vaccine) for People 18 Years of Age and Older

Posted 31 Aug 2016 by Drugs.com

CAMBRIDGE, Mass., Aug. 29, 2016 /PRNewswire/ – Seqirus announced today that the US Food and Drug Administration (FDA) has approved Afluria Quadrivalent (Influenza Vaccine) for use in persons 18 years of age and older. Afluria Quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Both Afluria Quadrivalent and Afluria (Influenza Vaccine), are available in the US for the 2016-2017 influenza season.1 Afluria Quadrivalent is the second quadrivalent influenza vaccine that Seqirus is offering this season after the FDA approved Flucelvax Quadrivalent (Influenza Vaccine) in May. Afluria Quadrivalent comes in single-dose, preservative-free pre-filled syringes while Afluria, indicated for persons 5 years of age and older, is available in prefilled syringes and ... Read more

Related support groups: Influenza, Vaccination, Afluria, Influenza Prophylaxis, Vaccination and Prophlaxis, Influenza Virus Vaccine, Inactivated, Afluria Quadrivalent

Sanofi Pasteur Announces FDA Approval of Quadracel DTaP-IPV Vaccine for Children 4 through 6 Years of Age

Posted 25 Mar 2015 by Drugs.com

SWIFTWATER, Pa., March 25, 2015 /PRNewswire/ – Sanofi Pasteur, the vaccines division of Sanofi , announced today that the U.S. Food and Drug Administration (FDA) has approved use of Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age. "The FDA approval of Quadracel vaccine provides health care providers with a new combination vaccine, potentially reducing the number of vaccine injections children aged 4 through 6 would need," said David P. Greenberg, M.D., Vice President, U.S. Scientific and Medical Affairs, Sanofi Pasteur. "Our goal is to help remove barriers to timely immunization and we think this combination vaccine could help ensure children are getting vaccinated in line with current ... Read more

Related support groups: Tetanus, Vaccination, Tetanus Toxoid, Pertussis, Polio, Diphtheria, Poliovirus Vaccine, Inactivated, Pertussis, Acellular, Vaccination and Prophlaxis, Tetanus Prophylaxis, Tetanus Toxoid Adsorbed, Poliomyelitis Prophylaxis, Pertussis Prophylaxis, Diphtheria Prophylaxis

New Bacterial Meningitis Vaccine Approved

Posted 26 Jan 2015 by Drugs.com

MONDAY, Jan. 26, 2015 – The Bexsero vaccine has been approved by the U.S. Food and Drug Administration to prevent the "serogroup B" form of bacterial meningitis among people aged 10 through 25. Meningococcal disease, or meningitis, is a life-threatening bacterial infection of the bloodstream and the lining that surrounds the brain and spinal cord. N. meningitis bacteria are commonly transmitted by coughing, kissing or sharing utensils, often in tight quarters such as a college dormitory. Some 500 cases of bacterial meningitis were recorded by the U.S. Centers for Disease Control and Prevention in 2012, of which 160 were caused by serogroup B, the FDA said. Meningococcal disease can be treated with antibiotics, although this treatment isn't always successful, the agency said. Bexsero was clinically evaluated among some 7,600 adolescents and young adults. The most common side effects ... Read more

Related support groups: Meningitis, Vaccination, Vaccination and Prophlaxis, Meningitis - Meningococcal

FDA Approves Flublok - New Seasonal Influenza Vaccine Made Using Novel Technology

Posted 16 Jan 2013 by Drugs.com

January 16, 2013 – The U.S. Food and Drug Administration today announced that it has approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. Flublok is approved for the prevention of seasonal influenza in people 18 through 49 years of age. Unlike current flu vaccines, Flublok does not use the influenza virus or eggs in its production. Flublok’s novel manufacturing technology allows for production of large quantities of the influenza virus protein, hemagglutinin (HA) – the active ingredient in all inactivated influenza vaccines that is essential for entry of the virus into cells in the body. The majority of antibodies that prevent influenza virus infection are directed against HA. While the technology is new to flu vaccine production, it is used to make vaccines that have been approved by the FDA ... Read more

Related support groups: Influenza, Vaccination, Influenza Prophylaxis, Influenza Virus Vaccine, Inactivated, Flu, Flu Prevention

Ask a Question